FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDG
Designation is based on clinical evidence from Phase 2a, including improvements in ataxia and other clinical measures after 24 weeks of GLM101 treatment Topline data from the randomized, placebo-controlled portion of the global Phase 2b POLAR study expected in the fourth quarter of 2026 SAN CARLOS, Calif., September 23, 2026 – Glycomine, Inc. announced today…
View details